KRAKOW, Poland, March 21,
2019 /PRNewswire/ -- Selvita (WSE: SLV), a clinical stage
company engaged in the research and development of novel cancer
therapies as well as provision of drug discovery and development
services, today announced that it will report fourth quarter and
year end 2018 financial results on Thursday,
March 28, 2019, and provide a corporate update. Management
will host a live video webcast at 10:00 a.m.
CET/5:00 a.m. EST (Polish
language).
The live webcast can be accessed live.selvita.com. An archived
version of the webcast will be available following the call in the
Investor Relations section of the Company's website at
www.selvita.com.
Selvita will also host a press conference for investors and
media in Warsaw, Poland.
About Selvita
Selvita is developing novel small molecule therapies that
address emerging targets in oncology with industry-leading research
expertise supported by a research services division. Pipeline
candidates apply diverse mechanisms directed at kinases, synthetic
lethality pathways, immuno-oncology pathways and other
cancer-related targets. SEL24/MEN1703 is a dual PIM/FLT3 kinase
inhibitor licensed to the Menarini Group in clinical development
for the treatment of acute myeloid leukemia. SEL120 is a CDK8
kinase inhibitor with potential for development in indications
including hematological malignancies and solid tumors. Selvita is
headquartered in Krakow with
offices in the U.S. and U.K.
Contact:
Julia Balanova (investors)
+1-646-378-2936
jbalanova@troutgroup.com
Rich Allan (media)
+1-646-378-2958
rallan@troutgroup.com
Malgorzata Syjud (corporate)
+48-660-797-362
malgorzata.syjud@selvita.com
View original
content:http://www.prnewswire.com/news-releases/selvita-to-host-conference-call-and-webcast-on-thursday-march-28-300816329.html
SOURCE Selvita